Federal award (DELIVERY ORDER, fiscal year 2024)
Recipient: THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2023-09-15 to 2025-09-14
Current total value of award: $593572
Description: BASE IDIQ TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS  TARGETING THE A2B ADENOSINE RECEPTOR FOR IMMUNOPREVENTION OF PANCREATIC CANCER